New research reveals that patients who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass much more quickly than those who end traditional lifestyle programs.
Published data in a major health publication points out that while obese people frequently drop about a fifth of their total mass while on the medication, the mass returns at an average rate of nearly a kilo each month once they quit.
"Users buying such treatments need to be aware of the risk of fast weight regain when the medication ends," cautioned expert Dr. Susan Jebb.
This pace of recovery implies a reversion to pre-treatment weight within about 18 months.
Analyzing Approaches
The research, which reviewed dozens of studies involving thousands of patients, contrasted the results of these new drugs with other pills.
Scientists emphasize that individuals who lose weight through lifestyle changes alone generally have a slower creep back—around 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Doctors suggest the way of the drugs is key to understanding the accelerated weight return.
The injections copy a natural hormone called GLP-1, which controls hunger.
"Sustained high doses of the hormone levels several times higher than the body's typical production could lead to the body to produce less of its own natural GLP-1, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication leads to appetite is no longer kept in check, making overeating a significant risk."
An Ongoing Issue?
Medical guidelines recommend the jabs for individuals with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals contend that, given the significant potential of relapse, the therapy should be considered life-long.
This perspective is echoed by pharmaceutical companies, who note that the findings "highlight the long-term nature of excess weight," similar to managing conditions like diabetes.
Patient Testimonies
Users who have discontinued the jabs report a intense resurgence of hunger.
"It felt as if a trigger that goes on and you become ravenous," recalled a patient.
The struggle is exacerbated if individuals have not established lasting dietary or behavioural modifications during therapy.
Significant Use
Recent estimates suggest that a significant number of adults in the UK have used weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is more common among females compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Ultimately, experts stress that while GLP-1 drugs are effective agents for weight loss, they are not a standalone fix and lasting health benefits hinges on ongoing lifestyle support.
